PAR2 deficiency impairs antitumor immunity and attenuates anti-PD1 efficacy in colorectal cancer
Open Access
- 2 April 2025
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 215, 107721
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81472246)
This publication has 62 references indexed in Scilit:
- Leveraging big data of immune checkpoint blockade response identifies novel potential targetsAnnals of Oncology, 2022
- Protease activated receptor 2 signaling promotes self-renewal and metastasis in colorectal cancer through β-catenin and periostinCancer Letters, 2021
- Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR–targeted therapy response in colorectal cancerCancer Letters, 2021
- PAR2 deficiency enhances myeloid cell-mediated immunosuppression and promotes colitis-associated tumorigenesisCancer Letters, 2020
- Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2019
- Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyCancer Cell, 2017
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic CellsCancer Cell, 2014
- Batf3‐dependent CD103+ dendritic cells are major producers of IL‐12 that drive local Th1 immunity against Leishmania major infection in miceEuropean Journal of Immunology, 2014
- The effects of stimulating protease-activated receptor-1 and -2 in A172 human glioblastomaJournal of Neural Transmission, 2001